OncoMatch/Clinical Trials/NCT05247268
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Is NCT05247268 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Megestrol Acetate 160 MG Oral Tablet and Medroxyprogesterone Acetate 500 MG for endometrial neoplasm malignant stage i.
Treatment: Megestrol Acetate 160 MG Oral Tablet · Medroxyprogesterone Acetate 500 MG · Triprorelin Acetate · Letrozole 2.5mg — To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Disease stage
Required: Stage EARLY-STAGE, GRADE I
Grade: I
early-stage endometrial cancer (endometrioid, grade I, without myometrial invasion)
Demographics
Prior therapy
Cannot have received: hormone treatment
Hormone treatment within 3 months before entering the trial
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05247268 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hormone treatment disqualifies patients from enrollment.
What disease stage is eligible?
Stage EARLY-STAGE or GRADE I is required.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages